Literature DB >> 28619505

Application of CRISPR-Cas9 in eye disease.

Wenyi Wu1, Luosheng Tang2, Patricia A D'Amore3, Hetian Lei4.   

Abstract

The system of clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated nuclease (Cas)9 is an effective instrument for revising the genome with great accuracy. This system has been widely employed to generate mutants in genomes from plants to human cells. Rapid improvements in Cas9 specificity in eukaryotic cells have opened great potential for the use of this technology as a therapeutic. Herein, we summarize the recent advancements of CRISPR-Cas9 use in research on human cells and animal models, and outline a basic and clinical pipeline for CRISPR-Cas9-based treatments of genetic eye diseases.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28619505     DOI: 10.1016/j.exer.2017.06.007

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  4 in total

1.  Phosphoinositide 3-kinase δ inactivation prevents vitreous-induced activation of AKT/MDM2/p53 and migration of retinal pigment epithelial cells.

Authors:  Haote Han; Na Chen; Xionggao Huang; Bing Liu; Jingkui Tian; Hetian Lei
Journal:  J Biol Chem       Date:  2019-08-29       Impact factor: 5.157

Review 2.  Drug delivery approaches for HuR-targeted therapy for lung cancer.

Authors:  Rajeswari Raguraman; Santny Shanmugarama; Meghna Mehta; Jo Elle Peterson; Yan D Zhao; Anupama Munshi; Rajagopal Ramesh
Journal:  Adv Drug Deliv Rev       Date:  2021-11-22       Impact factor: 15.470

Review 3.  Mitochondria: emerging therapeutic strategies for oocyte rescue.

Authors:  Zhixin Jiang; Huan Shen
Journal:  Reprod Sci       Date:  2021-03-12       Impact factor: 3.060

4.  Introduction of the MDM2 T309G Mutation in Primary Human Retinal Epithelial Cells Enhances Experimental Proliferative Vitreoretinopathy.

Authors:  Guohong Zhou; Yajiang Duan; Gaoen Ma; Wenyi Wu; Zhengping Hu; Na Chen; Yewlin Chee; Jing Cui; Arif Samad; Joanne A Matsubara; Shizuo Mukai; Patricia A D'Amore; Hetian Lei
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-10-01       Impact factor: 4.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.